Progress in Strategies for dosage regimen individualization

Current Topics in Medicinal Chemistry

Volumn 12, Issue 15, 2012, Pages 1669-1677

  Marouani, Hafedh ^a   Woloch, Christian ^a   Benay, Stephan ^a   Frances, Nicolas ^a,b   Iliadis, Athanassios ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Bayesian estimation; Dosage adjustment; Inter individual variability; Pharmacokinetics; Population approaches; Therapeutic drug monitoring

Indexed keywords

AMIKACIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

ARTICLE; BAYES THEOREM; CLINICAL PRACTICE; COMPUTER PROGRAM; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG MEGADOSE; DRUG MONITORING; GRAM NEGATIVE INFECTION; HEAD AND NECK TUMOR; HUMAN; INDIVIDUALIZATION; INFORMATION PROCESSING; NOMOGRAM; OSTEOSARCOMA; SIMULATION; STEADY STATE;

AMIKACIN; BAYES THEOREM; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; INDIVIDUALIZED MEDICINE; METHOTREXATE; MODELS, BIOLOGICAL; MODELS, STATISTICAL; NOMOGRAMS; SIROLIMUS;

EID: 84867529023     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612803531315     Document Type: Article

References (68)

1. Rowland, M.; Tozer, T.N. Clinical Pharmacokinetics and Pharmacodynamics: Concepts And Applications. 4th Revised ed.; Lippincott Williams and Wilkins: 2007; p 864.
2. Durieux, P.; Trinquart, L.; Colombet, I.; Niès, J.; Walton, R.; Rajeswaran, A.; Walther, M.R.; Harvey, E.; Burnand, B. Computerized advice on drug dosage to improve prescribing practice. Cochrane Database Syst. Rev., 2008, 16(3), CD002894.
3. Kang, J.S.; Lee, M.H. Overview of therapeutic drug monitoring. Korean J. Intern. Med., 2009, 24(1), 1-10.
4. Spector, R.; Park, G.D.; Johnson, G.F.; Vesell, E.S., Therapeutic drug monitoring. Clin. Pharmacol. Ther., 1988, 43(4), 345-353.
5. Rousseau, A.; Marquet, P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam. Clin. Pharmacol., 2002, 16(4), 253-262.
6. Alnaim, L., Therapeutic drug monitoring of cancer chemotherapy. J. Oncol. Pharm. Pract., 2007, 13(4), 207-221.
7. Calvert, A.H.; Newell, D.R.; Gumbrell, L.A.; O'Reilly, S.; M, M. B.; Boxall, F.E.; Siddik, Z. H.; Judson, I. R.; Gore, M. E.; Wiltshaw, E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol., 1989, 7(11), 1748-1756.
8. Chatelut, E.; Canal, P.; Brunner, V.; Chevreau, C.; Pujol, A.; Boneu, A.; Roché, H.; Houin, G.; Bugat, R. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J. Natl. Cancer Inst., 1995, 87(8), 573-580.
9. Gex-Fabry, M.; Balant, L.P. Considerations on data analysis using computer methods and currently avaibable software for personal computers. In Handbook of experimental pharmacology, Welling, P. G.; Balant, L. P., Eds. Spinger Verlag: Berlin, 1994; Vol. 110, pp 507-527.
10. Iliadis, A.; Brown, A.C.; Huggins, M.L. APIS: A software for identification, simulation and dosage regimen calculations in clinical and experimental pharmacokinetics. Comput. Methods Programs Biomed., 1992, 38(4), 227-239.
11. Jelliffe, R.W.; D'Argenio, D.Z.; Schumitzky, A.; Hu, L.; Liu, M. In The USC * PACK PC programs for planning, monitoring, and adjusting drug dosage regimens, Proceedings of the twenty-third Annual Meeting of the Association for the Advancement of Medical Instrumentation, Washington DC, May 14-18, 1988; Washington DC, 1988; p 51.
12. Proost, J.H.; Meijer, D.K. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput. Biol. Med., 1992, 22(3), 155-163.
13. Graf, N.; Winkler, K.; Betlemovic, M.; Fuchs, N.; Bode, U. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J. Clin. Oncol., 1994, 12(7), 1443-1451.
14. Minami, H.; Beijnen, J.H.; Verweij, J.; Ratain, M.J. Limited sampling model for area under the concentration time curve of total topotecan. Clin. Cancer Res., 1996, 2(1), 43-46.
15. Jelliffe, R. W.; Maire, P.; Sattler, F.; Gomis, P.; Tahani, B. Adaptive control of drug dosage regimens: basic foundations, relevant issues, and clinical examples. Int. J. Biomed. Comput., 1994, 36(1-2), 1-23.
16. Jelliffe, R.; Bayard, D.; Milman, M.; Guilder, M. V.; Schumitzsky, A. Achieving target goals most precisely using non parametric models and "Multiple Model" design of dosage regimens. Ther. Drug Monit., 2000, 22(3), 346-353.
17. Bayard, D.S.; Jelliffe, R.W. A bayesian approach to tracking patient having changing pharmacokinetic parameters. J. Pharmacokinet. Pharmacodyn., 2004, 31(1), 75-107.
18. Thomson, A.H.; Whiting, B. Bayesian parameter estimation and population pharmacokinetics. Clin. Pharmacokinet., 1992, 22(6), 447-467.
19. Gross, A.S. Best practice in therapeutic drug monitoring. Br. J. Clin. Pharmacol., 2001, 52(Suppl 1), 5-10.
20. Marouani, H.; Zografidis, A.; Iliadis, A. Kinetic nomograms assist individualization of drug regimens. Clin. Pharmacokinet., 2011, 50(12), 773-779.
21. Iliadis, A.; Bachir-Raho, M.; Bruno, R.; Favre, R. Bayesian estimation and prediction of clearance in high-dose methotrexate infusions. J. Pharmacokinet. Biopharmaceut., 1985, 13(1), 101-115.
22. Bleyer, W.A. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer, 1978, 41(1), 36-51.
23. Bruno, R.; Iliadis, A.; Favre, R.; Lena, N.; Imbert, A.M.; Cano, J.P. Dosage predictions in high-dose methotrexate infusions. Part 2: Bayesian estimation of methotrexate clearance. Cancer Drug Delivery, 1985, 2(4), 277-283.
24. Kerr, I.G.; Jolivet, J.; Collins, J.M.; Drake, J.C.; Chabner, B.A. Test dose for predicting high-dose methotrexate infusions. Clin. Pharmacol. Ther., 1983, 33(1), 44-51.
25. Cano, J.P.; Bruno, R.; Lena, N.; Favre, R.; Iliadis, A.; Imbert, A.M. Dosage predictions in high-dose methotrexate infusions. Part 1: Evaluation of the classic test-dose protocol. Cancer Drug Deliv., 1985, 2(4), 271-276.
26. Sheiner, L.B.; Beal, S.L., Some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharmaceut., 1981, 9(4), 503-512.
27. Zaske, D.E. Aminoglycosides. In Applied pharmacokinetics., 2nd ed.; Evans, W.E.; Schentag, J.J.; Jusko, W.J., Eds. Applied Therapeutics, Spokane, WA: 1986; pp 331-381.
28. Kovarik, J.M.; Hoepelman, I.M.; Verhoefl, J. Once-Daily Aminoglycoside Administration: New Strategies for an Old Drug. Eur. J. Clin. Microbiol. Infect. Dis., 1989, 8 (9), 761-769.
29. Garraffo, R.; Iliadis, A.; Cano, J. P.; Dellamonica, P.; Lapalus, P. Application of bayesian estimation for prediction of appropriate dosage regimen of amikacin. J. Pharmaceut. Sci., 1989, 78(9), 753-757.
30. Bressolle, F.; Gouby, A.; Martinez, J. M.; Joubert, P.; Saissi, G.; Guillaud, R.; Gomeni, R. Population pharmacokinetics of amikacin in critically ill patients. Antimicrob. Agents Chemother., 1996, 40(7), 1682-1689.
31. Nicolau, D.P.; Freeman, C.D.; Belliveau, P.P.; Nightingale, C.H.; Ross, J.W.; Quintiliani, R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob. Agents Chemother., 1995, 39(3), 650-655.
32. Chan, R.A.; Benner, E.J.; Hoeprich, R.D. Gentamicin therapy in renal failure: a nomogram for dosage. Ann. Intern. Med., 1972, 76(5), 773-778.
33. Sarubbi, F.A.; Hull, J.H. Amikacin serum concentrations: predictions of levels and dosage guidelines. Ann. Intern. Med. 1978, 89(5 Pt 1), 612-618.
34. Burton, M.E.; Brater, D.C.; Chen, P.S.; Day, R.B.; Huber, P.J.; Vasko, M.R.A Bayesian feedback method of aminoglycoside dosing. Clin. Pharmacol. Ther., 1985, 37(3), 349-357.
35. Lenert, L.A.; Klostermann, H.; Coleman, R.W.; Lurie, J.; Blaschke, T.F. Practical computer-assisted dosing for aminoglycoside antibiotics. Antimicrob Agents Chemother., 1992, 36(6), 1230-1235.
36. Hickling, K.; Begg, E.; Moore, M.L. A prospective randomised trial comparing individualized pharmacokinetic dosage prediction for aminoglycosides with prediction based on estimated creatinine clearance in critically ill patients. Intensive Care Med., 1989, 15(4), 233-237.
37. Iliadis, A.; Bruno, R.; Cano, J.P. Dynamical dosage regimen calculations in linear pharmacokinetics. Comput. Biomed. Res., 1988, 21, 203-220.
38. Kawamata, S.; Sakaida, H.; Hori, T.; Maeda, M.; Uchiyama, T. The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines. Blood, 1998, 91(2), 561-569.
39. Kahan, B.D.; Keown, P.; Levy, G.A.; Johnston, A. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin. Therapeut., 2002, 24(3), 330-350.
40. Holt, D.W.; Denny, K.; Lee, T.D.; Johnston, A. Therapeutic monitoring of sirolimus: its contribution to optimal prescription. Transplant Proc., 2003, 35(3 Suppl), 157-161.
41. Kuypers, D.R. Benefit-risk assessment of sirolimus in renal transplantation. Drug Safety, 2005, 28(2), 153-181.
42. Oellerich, M.; Armstrong, V.W.; Streit, F.; Weber, L.; Tönshoff, B. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. Clin. Biochem., 2004, 37(6), 424-428.
43. Aspeslet, L.J.; Yatscoff, R.W. Requirements for therapeutic drug monitoring of sirolimus, an immunosuppressive agent used in renal transplantation. Clin. Therapeut., 2000, 22, (Suppl B), 86-92.
44. Meier-Kriesche, H.U.; Kaplan, B. Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations. Clin. Therapeut., 2000, 22(Suppl B), 93-100.
45. Zimmerman, J.J. Exposure-response relationships and drug interactions of sirolimus. AAPS J., 2004, 6(4), e28.
46. Cattaneo, D.; Merlini, S.; Pellegrino, M.; Carrara, F.; Zenoni, S.; Murgia, S.; Baldelli, S.; Gaspari, F.; Remuzzi, G.; Perico, N. Therapeutic drug monitoring of sirolimus: effect of concomitant immunosuppressive therapy and optimization of drug dosing. Am. J. Transplant., 2004, 4(8), 1345-1351.
47. Steimer, J.L.; Vozeh, S.; Racine-Poon, A.; Holford, N.H.G.; O'Neil, R. The population approach: Rationale, methods, applications in clinical pharmacology and drug development. In Pharmacokinetics of Drugs, Handbook of Experimental Pharmacology, Welling, P. G.; Balant, L. P., Eds. Springer-Verlag: Berlin, 1994; pp 405-451.
48. Iliadis, A.; Bruno, R.; Cano, J.P. Steady-state dosage regimen calculations in linear pharmacokinetics. Int. J. Bio-Med. Comput., 1986, 18, 167-182.
49. Djebli, N.; Rousseau, A.; Hoizey, G.; Rerolle, J.P.; Toupance, O.; LeMeur, Y.; Marquet, P. Sirolimus population pharmacokinetic/pharmacogenetic analysis and Bayesian modelling in kidney transplant recipients. Clin. Pharmacokinet., 2006, 45(11), 1135-1148.
50. Watson, C.J.E.; Firth, J.; Williams, P.F.; Bradley, J.R.; Pritchard, N.; Chaudhry, A.; Smith, J.C.; Palmer, C.R.; Bradley, J.A. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am. J. Transplant., 2005, 5(10), 2496-2503.
51. Flechner, S.M.; Goldfarb, D.; Modlin, C.; Feng, J.; Krishnamurthi, V.; Mastroianni, B.; Savas, K.; Cook, D.J.; Novick, A.C. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation, 2002, 74(8), 1070-1076.
52. MATLAB High-performance Numeric Computation and Visualization Software, 7.0; The Math Works: Natick MA, 2004.
53. Gilbert, D.N. Once-daily aminoglycoside therapy. Antimicrob. Agents Chemother., 1991, 35(3), 399-405.
54. Zhanel, G.G.; Hoban, D.J.; Harding, G.K. The postantibiotic effect: a review of in vitro and in vivo data. Ann. Pharmacother., 1991, 25(2), 153-163.
55. Rybak, M.J.; Abate, B.J.; Kang, S.L.; Ruffing, M.J.; Lerner, S.A.; Drusano, G. L. Prospective evaluation of the effects of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob. Agents Chemother., 1999, 43(7), 1549-1555.
56. Anaizi, N. Once-daily dosing of aminoglycosides: a consensus document. Int. J. Clin. Pharmacol. Ther., 1997, 35(6), 223-226.
57. Gilbert, D.N.; Moellering, R.C.; Sande, M.A. The Sanford guide to antimicrobial therapy. 30th ed.; Hyde Park (VT): Antimicrobial Therapy Inc, 2000: 2000.
58. Demczar, D.D.; Nafziger, A. N.; Bertino, J.S. Pharmacokinetics of gentamicin at traditional versus high doses: implications for oncedaily aminoglycoside dosing. Antimicrob. Agents Chemother., 1997, 41(5), 1115-1119.
59. McNamara, D.R.; Nafziger, A.N.; Menhinick, A.M.; Bertino, J.S., A dose-ranging study of gentamicin pharmacokinetics: implications for extended interval aminoglycoside therapy. J. Clin. Pharmacol., 2001, 41(4), 374-377.
60. Tod, M. M.; Padoin, C.; Petitjean, O. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods? Clin. Pharmacokinet., 2001, 40(11), 803-814.
61. Bayard, D.S.; Milman, M.H.; Schumitzky, A. Design of dosage regimens: a multiple model stochastic control approach. Int. J. Bio-Med. Comput. 1994, 36, 103-115.
62. Iliadis, A.; Barbolosi, D. Dosage regimen calculations with optimal control theory. Int. J. Bio-Med. Comput., 1994, 36, 87-93.
63. Duffull, S.B.; Begg, E.J.; Robinson, B.A.; Deely, J.J. A sequential Bayesian algorithm for dose individualisation of carboplatin. Cancer Chemother. Pharmacol., 1997, 39(4), 317-326.
64. Rousseau, A.; Marquet, P.; Debord, J.; Sabot, C.; Lachâtre, G. Adaptive control methods for the dose individualisation of anticancer agents. Clinical Pharmacokinet., 2000, 38(4), 315-353.
65. Proost, J.H. Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting. Int. J. Clin. Pharmacol. Ther., 1995, 33(10), 531-536.
66. Jelliffe, R.W.; Schumitzky, A.; VanGuilder, M.; Liu, M.; Hu, L.; Maire, P.; Gomis, P.; Barbaut, X.; Tahani, B. Individualizing drug dosage regimens: Roles of population pharmacokinetic and dynamic models, bayesian fitting, and adaptive control. Ther. Drug Monit., 1993, 15, 380-393.
67. Jelliffe, R.W.; Schumitzky, A.; Bayard, D.; Milman, M.; Van-Guilder, M.; Wang, X.; Jiang, F.; Barbaut, X.; Maire, P., Modelbased, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals. Clin. Pharmacokinet., 1998, 34(1), 57-77.
68. Bondareva, I.B.; Jelliffe, R.W.; Sokolov, A.V.; Tischenkova, I.F. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage. J. Clin. Pharm. Ther., 2004, 29(2), 105-120.